The president of Medicines for Europe talks about the need for an urgent pause in the adoption of the Extended Producer Responsibility (EPR) scheme under the Urban Waste Water Treatment Directive (UWWTD) to safeguard patient access and medicine supply while a fairer, more practical solution is reviewed.
Read the comment of our President and full Article below.
The president of Medicines for Europe talks about what the European healthcare sector needs and what the off-patent sector can deliver.
Read the comment of our President and full Article below.
At Medicines for Europe’s Legal and Annual Conferences in Brussels last week, multiple key issues were discussed to support the role of generics and biosimilars at a critical time for EU pharma reform.
Read the comment of our President and full Article below.
President of Medicines for Europe, Stephan Eder, highlights the association’s priorities for driving change in the off-patent medicines sector, addressing how Europe can move beyond price-driven policies to better support innovation, resilience and patient access.
Read the full Article below.
Director of Biosimilar Policy & Science at Medicines for Europe, Julie Maréchal-Jamil, discusses the necessary strategies at both European and national levels to ensure the continued advantages of biosimilar medicines.
Read the full Article below.
Newly appointed Medicines for Europe President Stephan Eder discusses the association’s key priorities with Generics Bulletin, focusing on ensuring a sustainable future for the generics, biosimilars, and value-added medicines industry in Europe.
Read the full Article below.
The president of Medicines for Europe considers that the supply of essential drugs is at risk if governments do not allow the price of cheap drugs to be revised in line with inflation.
Read the comment of our President and full Article below.
The legislative reform being prepared by the EU plans to promote the use of already approved drugs for new ailments. This route allows to accelerate the approval of treatments and save costs in research.
Read the comment of our Director general and full Article below
Adrian van den Hoven, chair of the International Generic and Biosimilar Medicines Association (IGBA), which aims to foster market access for generic medicines, said that the evergreening of patent agreements artificially stretches monopolies and harms access to medicines.
Read the full Article below
Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector.